Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine

Autoři: Kenneth Hugdahl, PhD.
Rok vydání: 2026
Typ publikace: Článek v odborném periodiku
Periodikum: Psychiatry Research
Bibliografická citace: KROKEN, R., JOHNSEN, E., ALISAUSKIENE, R., ANDA, L. G., BARTZ-JOHANNESEN, Ch., BERLE, J. O., BJARKE, J., BRUSERUD, O., FATHIAN, F., FLEISCHHACKER, W. W., HUGDAHL, Kenneth, JOA, I., KJELBY, E., LARSEN, T. K., LØBERG, E.-M., RATKE, I., RETTENBACHER, M., SINKEVICIUTE, I., SKREDE, S., STABELL, L. A., STEEN, V. M., TORSVIK, A., REITAN, S. K. Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine. Psychiatry Research. 2026, 364(June 2026), 117266. ISSN 0165-1781. E-ISSN 1872-7123
Dostupné z: doi:10.1016/j.psychres.2026.117266.
DOI: 10.1016/j.psychres.2026.117266
ID: 651573
Online záznam: Zobrazit online záznam

Abstrakt

BACKGROUND: Schizophrenia is associated with inflammation. Antipsychotic drugs have anti-inflammatory properties but few antipsychotics have been compared head-to head. The aim of this study was to evaluate the immunomodulatory effects of three pharmacologically different atypical antipsychotics, amisulpiride, aripiprazole and olanzapine, in patients with schizophrenia-spectrum disorders. METHODS: The study reports a predefined secondary outcome of the BeSt InTro-study, a double blind randomized head-to-head trial comparing amisulpride, aripiprazole and olanzapine. Patients with a schizophrenia-spectrum disorder (N=144) were randomized to the different treatment arms, and serum levels of nine cytokines (interleukin [IL]-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17A, interferon [IFN]-γ, and tumor necrosis factor [TNF]-α) were assessed at baseline and weeks 1, 3, 6, 12, 26, 39 and 52. A combined pro-inflammatory variable was constructed from IL1-β and TNF-α. The primary analyses were done in per protocol (PP) data in the drug-naïve sample (n = 56). Changes in cytokine levels between baseline and the end of the study were analyzed in a mixed effects model with amisulpride as the reference drug. RESULTS: Treatment with amisulpride was associated with a reduction in pro-inflammatory IL-1β levels over 12 months, this change was statistically different compared to the change in aripiprazole and olanzapine. A significant difference between the influence of amisulpride compared to aripiprazole on the anti-inflammatory cytokine IL-10 was detected. Aripiprazole reduced IL-12p70 more than amisulpride. The combined pro-inflammatory variable decreased from baseline to week 52 with a magnitude of 0.52 standard deviation (SD) after treatment with amisulpride.. CONCLUSION: Patients treated with amisulpride showed greater anti-inflammatory changes in cytokine serum levels than those treated with aripiprazole or olanzapine. FUNDING: The Research Council of Norway, the Western Norway Regional Health Trust, and Klinbeforsk supported the study.